POLG Enzyme Could Be New Target for Breast Cancer Care
Researchers identified that targeting this enzyme may help stop the spread of aggressive triple-negative breast cancer cells.
Updated on Oct. 31, 2026 in Cancer
Researchers have identified that the enzyme POLG promotes the spread of triple-negative breast cancer (TNBC) by fueling mitochondrial energy production. This finding suggests that blocking this enzyme could serve as a potential therapeutic strategy for treating aggressive breast cancer cases.
Why it matters
High levels of POLG are linked to worse outcomes in patients with triple-negative breast cancer, a highly aggressive subtype. By understanding how cancer-associated fibroblasts drive this metabolic reprogramming, researchers are identifying new vulnerabilities in tumor growth.
This preclinical study demonstrates that POLG promotes metastasis through enhanced mitochondrial DNA replication and oxidative phosphorylation. Researchers found that knocking down or pharmacologically inhibiting this enzyme significantly reduced the spread of TNBC cells.
The players
Cell Death & Disease
A peer-reviewed scientific journal publishing research on cell biology and the mechanisms of disease.
The details
POLG acts as a critical enzyme that oversees the replication and translation of mitochondrial DNA, directly increasing the quantity and function of energy-producing complexes. In TNBC cells, cancer-associated fibroblasts trigger the cooperation of two proteins, ERRα and PGC-1α, to ramp up POLG expression. This results in metabolic reprogramming that allows cancer cells to boost ATP production and survival through both internal and external mitochondrial DNA sources.
Timeline
October 31, 2026: Research article published in Cell Death & Disease.
Health Landscape
This research expands the field of metabolic oncology, moving beyond traditional glucose-focused models to target mitochondrial maintenance. It positions POLG as a potential focus in the pursuit of more targeted therapies for aggressive breast cancer subtypes.
This discovery is a preliminary step in identifying new drug targets and does not yet change current treatment protocols for patients. If you or a loved one are managing a breast cancer diagnosis, discuss your tumor subtype and any available clinical trials with your oncology team.
The takeaway
Targeting mitochondrial health could eventually offer new ways to curb the spread of aggressive breast cancer cells. Always prioritize discussions with your physician regarding your specific cancer subtype and the most appropriate, evidence-based care plan for your situation.
Further reading
For more on the current state of breast cancer research and management, visit our Cancer section.
More information
View the complete peer-reviewed research article for detailed study methodology.
